We're talking about an increase. What is not clear in what was disclosed in terms of principles of the agreement, is we don't know exactly if that protection will be extended as well to non-innovative drugs. If that is the case, the cost will be more important, but we're talking between 6% and 12%, more or less.
On February 13th, 2014. See this statement in context.